Clinical Characteristics of 100 Patients Who Received Allogeneic Transplants With or Without Subsequent Infusions of Prophylactic Cytotoxic T Cells
. | Study Group (n = 39) . | Control Group (n = 61) . | . |
---|---|---|---|
Age at treatment (mean and range) | 9.5 yr (9 mo to 20 yr) | 9.8 yr (8 mo to 23 yr) | |
Male:female | 18:21 | 33:28 | |
Diagnostic category | |||
Standard risk* | 19 | 24 | |
High risk-151 | 20 | 37 | |
Type of transplant received | |||
Mismatched family member | |||
5/6 match | 2 | 11 | |
4/6 match | 3 | 9 | |
3/6 match | 1 | 3 | |
Unrelated donor | |||
6/6 match | 20 | 22 | |
5/6 match | 13 | 16 | |
No. of developing EBV lymphoma | 0 | 7 (2 mismatched family member, 5 unrelated donor) | P = .03 |
. | Study Group (n = 39) . | Control Group (n = 61) . | . |
---|---|---|---|
Age at treatment (mean and range) | 9.5 yr (9 mo to 20 yr) | 9.8 yr (8 mo to 23 yr) | |
Male:female | 18:21 | 33:28 | |
Diagnostic category | |||
Standard risk* | 19 | 24 | |
High risk-151 | 20 | 37 | |
Type of transplant received | |||
Mismatched family member | |||
5/6 match | 2 | 11 | |
4/6 match | 3 | 9 | |
3/6 match | 1 | 3 | |
Unrelated donor | |||
6/6 match | 20 | 22 | |
5/6 match | 13 | 16 | |
No. of developing EBV lymphoma | 0 | 7 (2 mismatched family member, 5 unrelated donor) | P = .03 |
*Chronic myeloid leukemia in chronic or accelerated phase; acute myeloid or lymphoblastic leukemia in first or second remission; and metabolic storage diseases.
Chronic myeloid leukemia in or after blast crisis; acute myeloid or lymphoblastic leukemia in relapse or greater than second remission; myelodysplasia; secondary acute myeloid leukemia; and familial erythrophagocytic lymphohistiocytosis.